CN Patent

CN110386974B — Glp-1衍生物及其治疗用途

Assigned to Hangzhou Xianweida Biotechnology Co ltd · Expires 2022-12-09 · 3y expired

What this patent protects

本发明提供了GLP‑1(7‑37)多肽类似物、该类似物的脂肪酸修饰的衍生物和包含该衍生物的药物。另外，本发明还提供了该衍生物的制备方法以及该衍生物在制备药物中的用途。

USPTO Abstract

本发明提供了GLP‑1(7‑37)多肽类似物、该类似物的脂肪酸修饰的衍生物和包含该衍生物的药物。另外，本发明还提供了该衍生物的制备方法以及该衍生物在制备药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110386974B
Jurisdiction
CN
Classification
—
Expires
2022-12-09
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Xianweida Biotechnology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.